Analysis of the effectiveness of the drug based on succinic acid salts for the treatment of osteoporosis
Almazov NMRC of the Ministry of health of the Russian Federation
Institute of theoretical and experimental biophysics
Institute of experimental medicine
Brief summary
We performed an experimental analysis of the pharmacological effectiveness of the drug, created on the basis of a complex of acid salts of calcium and magnesium of the natural succinic acid conformer, in comparison with the well-known anti-osteoporotic drug. Testing was carried out on a model of osteoporosis in female rats that were given prednisolone twice after bilateral ovariectomy. The increment in weight indicators, the increase in the level of calcium and collagen in the tissue of the femur revealed the higher efficiency of the new drug in the correction of simulated potentiopausal osteoporosis.
6. Maevskii E.I., Ychitel M.L., Bairamov A.A., Shabanov P.D. i dr. Korrekciya gormonalnoi aktivnosti sybstratnimi kompoziciyami y myjchin i jenshin. Gastroenterologiya Sankt-Peterbyrga. 2017. 2-3. S.55-56.
7. Medicina klimakteriya / Pod red. V.P. Smetnik.- Yaroslavl: «Izd. Litera», 2006. 848 s.
8. Mitohondrialnie processi vo vremennoi organizacii jiznedeyatelnosti. Sb. Pod red. M.N. Kondrashovoi, V.V. Dinnika, U.G. Kaminskogo, E.I. Maevskogo, E.A. Okon. Pyshino, 1978, 182 s.
9. Mitohondrii v patologii. Sb. Pod red. M.N.Kondrashovoi, U.G.Kaminskogo, E.I.Maevskogo, E.V.Grishina. Pyshino, 2001, 258 s.
10. Riggz B.L., Melton D. Osteoporoz. Etiologiya, diagnostika, lechenie. «Izdatel-stvo Binom», 2000; s. 309-13.
11. Rykovodstvo po eksperimentalnomy (doklinicheskomy) izycheniu novih farmakologicheskih veshestv. Pod obshei redakciei R. Y. Habrieva - 2-izd., pererab. i dop. - M.: OAO "Izdatelstvo "Medicina", 2005, 832 s.
12. Salyhov V.V., Kovalevskaya E.A. Glukortikoid-indycirovannii osteoporoz: sovremennoe sostoyanie problemi//Biomediicnskii jyrnal. medline.ru 2018. T. 19, ST. 61, s. 832-860.
13. Stiven Hodjkin. Klinika Meio ob Osteoporoze. Per. s ang. M. Astrel. AST. 2007. 237 s.
14. Terapevticheskoe deistvie yantarnoi kisloti. Sb. Pod red. M.N.Kondrashovoi. Pyshino, 1976, 255 s.
15. Ychitel M.L., Bolotanova M.K., Nechaev A.N, Vasileva A.A., Grishina E.N., Pogorelov A.G., Pogorelova V.N., Bogdanova L.A., Maevskii E.I. Popitka metaboliche-skoi korrekcii osteopenii v eksperimente i klinike pri zavershenii ovylyatornogo cik-la.//Biomedicinskii jyrnal medline.ru. 2013, T. 14, ST. 93, s. 1211-1217.
16. Sharaev, P.N. Metod opredeleniya svobodnogo i svyazannogo oksiprolina v sivo-rotke krovi // Laboratornoe delo. 1981, 5, c.283-285.
18. Yantarnaya kislota v medicine, pishevoi promishlennosti, selskom hozyaistve. Sb. Pod red. M.N.Kondrashovoi, U.G.Kaminskogo, E.I.Maevskogo. Pyshino, 1996, 300 s.
19. Black D.M., Rosen C.J.. Postmenopausal osteoporosis // N Engl J Med. 2016; 74:254-262.
20. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. Effect of osteoporosis treatment on mortality: a meta-analysis // J Clin Endocrinol Metab. 2010; 95:1174-1181
21. Brown J.P., Morin S., Leslie W., et al.: Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays // Can Fam Physician. 2014, 60:324-333.
22. Cauley J.A., Thompson D.E., Ensrud K.C. et al. Risk of mortality following clinical fractures // Osteoporosis Int., 2000; 11: 556-561.
23. EFFO and IOF (European Foundation For Osteoporosis and International Osteoporosis Foundation). Who are candidates for prevention and treatment for osteoporosis? // Osteoporos Int 1997; 7: 1.
24. He W., Mlao F., Lin D., Schwandner R.T., Wang Z., Gao J., Chen J.-L., Tlan H., Ling L. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors // Nature. 2004. 429, r. 188-193.
25. International Osteoporosis Foundation 2010. http://www.iofbonehealth.org/facts-and-statistics.html#factsheet-category-22.
26. Kanis J.A.. World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Health-Care Level Technical Report Sheffield. UK: WHO Collaborating Centre, University of Sheffield; 2008.
27. Koivunen P, Hirsilä M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF.//J Biol Chem. 2007 Feb 16;282(7):4524-32. doi: 10.1074/jbc.M610415200. Epub 2006 Dec 19.
28. MacLean C., Newberry S., Maglione M. et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis // Ann Intern Med 200;148:197-213
29. Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society // Menopause 2010; 17 (1): 25-54.
30. W.L. Miller Steroid hormone synthesis in mitochondria //Molecular and Cellular Endocrinology. 2013, V. 379, Iss. 1-2, r. 62-73. doi.org/10.1016/j.mce.2013.04.014
31. National Osteoporosis Foundation. Advocacy News & Updates. America?s Bone Health: The State of Osteoporosis and Low Bone Mass. Accessed April 18, 2011. 14. National Osteoporosis Foundation. Fast Facts. Accessed April 18, 2011
32. Semenza G. L. Hypoxia-inducible factors in physiology and medicine. //Cell. 2012, v.148, ?3, r. 399-408.
33. Vasilieva A.A.,. Simonova M.A,. Bairamov A.A, Grishina E.V., Uchitel M.L, Maevsky E.I.Sorrection of the functional state of female rats after unilateral ovariectomy using a succinate containing composition. Cardiometry, 2017, 10; p.86-92;
34. WHO (World Health Organization), FRAX (Fracture Risk Assessment Tool), Calculation Tool. Accessed November 11, 2012. shef.ac.uk/FRAX/tool.jspcountry=9.
35. Yuqi-Guo, Chengzhi-Xie, Xiyan-Li, Jian-Yang, Tao-Yu, Ruohan-Zhang, Tianqing-Zhang, D. Saxena, M. Snyder, Yingjie-Wu, Xin-Li Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis //Nat Commun. 2017; 8: 15621. Published online 2017 May 31. doi:10.1038/ncomms15621